FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2500897030> ?p ?o ?g. }

• W2500897030 endingPage "5746" @default.
• W2500897030 startingPage "5738" @default.
• W2500897030 abstract "Abstract Purpose: Pazopanib is a tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma and soft tissue sarcoma. Retrospective analyses have shown that an increased median progression-free survival and tumor shrinkage appear in patients with higher plasma trough levels (Cmin). Therefore, patients with low Cmin might benefit from pharmacokinetically guided individualized dosing. Experimental Design: We conducted a prospective multicenter trial in 30 patients with advanced solid tumors. Pazopanib Cmin was measured weekly by LC-MS/MS. At weeks 3, 5, and 7, the pazopanib dose was increased if the measured Cmin was &lt;20 mg/L and toxicity was &lt;grade 3. Results: In total, 17 patients had at least one Cmin &lt;20 mg/L at weeks 3, 5, and 7. Of these, 10 were successfully treated with a pharmacokinetically guided dose escalation, leading to daily dosages ranging from 1,000 to 1,800 mg. Cmin in these patients increased significantly from 13.2 (38.0%) mg/L [mean (CV%)] to 22.9 mg/L (44.9%). Thirteen patients had all Cmin levels ≥20.0 mg/L. Of these, 9 patients with a high Cmin of 51.3 mg/L (45.1%) experienced ≥grade 3 toxicity and subsequently required a dose reduction to 600 or 400 mg daily, yet in these patients, Cmin remained above the threshold at 28.2 mg/L (25.3%). Conclusions: A pharmacokinetically guided individualized dosing algorithm was successfully applied and evaluated. The dosing algorithm led to patients being treated at dosages ranging from 400 to 1,800 mg daily. Further studies are needed to show a benefit of individualized dosing on clinical outcomes, such as progression-free survival. Clin Cancer Res; 22(23); 5738–46. ©2016 AACR. See related commentary by Ornstein and Rini, p. 5626" @default.
• W2500897030 created "2016-08-23" @default.
• W2500897030 creator A5000418012 @default.
• W2500897030 creator A5010531755 @default.
• W2500897030 creator A5038707468 @default.
• W2500897030 creator A5042739248 @default.
• W2500897030 creator A5050202217 @default.
• W2500897030 creator A5051744290 @default.
• W2500897030 creator A5062227574 @default.
• W2500897030 creator A5071612016 @default.
• W2500897030 creator A5074174053 @default.
• W2500897030 creator A5078332643 @default.
• W2500897030 date "2016-11-30" @default.
• W2500897030 modified "2023-10-02" @default.
• W2500897030 title "Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients" @default.
• W2500897030 cites W1736458389 @default.
• W2500897030 cites W1976487307 @default.
• W2500897030 cites W1985610919 @default.
• W2500897030 cites W1994344097 @default.
• W2500897030 cites W2007545333 @default.
• W2500897030 cites W2028713529 @default.
• W2500897030 cites W2029169364 @default.
• W2500897030 cites W2045432173 @default.
• W2500897030 cites W2052683946 @default.
• W2500897030 cites W2078330700 @default.
• W2500897030 cites W2081683283 @default.
• W2500897030 cites W2095771928 @default.
• W2500897030 cites W2099022883 @default.
• W2500897030 cites W2100116917 @default.
• W2500897030 cites W2101776780 @default.
• W2500897030 cites W2115125611 @default.
• W2500897030 cites W2127447993 @default.
• W2500897030 cites W2133354058 @default.
• W2500897030 cites W2152036882 @default.
• W2500897030 cites W2152405009 @default.
• W2500897030 cites W2162424705 @default.
• W2500897030 cites W2323642978 @default.
• W2500897030 doi "https://doi.org/10.1158/1078-0432.ccr-16-1255" @default.
• W2500897030 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27470967" @default.
• W2500897030 hasPublicationYear "2016" @default.
• W2500897030 type Work @default.
• W2500897030 sameAs 2500897030 @default.
• W2500897030 citedByCount "62" @default.
• W2500897030 countsByYear W25008970302016 @default.
• W2500897030 countsByYear W25008970302017 @default.
• W2500897030 countsByYear W25008970302018 @default.
• W2500897030 countsByYear W25008970302019 @default.
• W2500897030 countsByYear W25008970302020 @default.
• W2500897030 countsByYear W25008970302021 @default.
• W2500897030 countsByYear W25008970302022 @default.
• W2500897030 countsByYear W25008970302023 @default.
• W2500897030 crossrefType "journal-article" @default.
• W2500897030 hasAuthorship W2500897030A5000418012 @default.
• W2500897030 hasAuthorship W2500897030A5010531755 @default.
• W2500897030 hasAuthorship W2500897030A5038707468 @default.
• W2500897030 hasAuthorship W2500897030A5042739248 @default.
• W2500897030 hasAuthorship W2500897030A5050202217 @default.
• W2500897030 hasAuthorship W2500897030A5051744290 @default.
• W2500897030 hasAuthorship W2500897030A5062227574 @default.
• W2500897030 hasAuthorship W2500897030A5071612016 @default.
• W2500897030 hasAuthorship W2500897030A5074174053 @default.
• W2500897030 hasAuthorship W2500897030A5078332643 @default.
• W2500897030 hasConcept C112705442 @default.
• W2500897030 hasConcept C121608353 @default.
• W2500897030 hasConcept C126322002 @default.
• W2500897030 hasConcept C126894567 @default.
• W2500897030 hasConcept C162156334 @default.
• W2500897030 hasConcept C22979827 @default.
• W2500897030 hasConcept C2777288759 @default.
• W2500897030 hasConcept C2778335254 @default.
• W2500897030 hasConcept C2778439243 @default.
• W2500897030 hasConcept C2778820342 @default.
• W2500897030 hasConcept C2779490328 @default.
• W2500897030 hasConcept C29730261 @default.
• W2500897030 hasConcept C71924100 @default.
• W2500897030 hasConcept C98274493 @default.
• W2500897030 hasConceptScore W2500897030C112705442 @default.
• W2500897030 hasConceptScore W2500897030C121608353 @default.
• W2500897030 hasConceptScore W2500897030C126322002 @default.
• W2500897030 hasConceptScore W2500897030C126894567 @default.
• W2500897030 hasConceptScore W2500897030C162156334 @default.
• W2500897030 hasConceptScore W2500897030C22979827 @default.
• W2500897030 hasConceptScore W2500897030C2777288759 @default.
• W2500897030 hasConceptScore W2500897030C2778335254 @default.
• W2500897030 hasConceptScore W2500897030C2778439243 @default.
• W2500897030 hasConceptScore W2500897030C2778820342 @default.
• W2500897030 hasConceptScore W2500897030C2779490328 @default.
• W2500897030 hasConceptScore W2500897030C29730261 @default.
• W2500897030 hasConceptScore W2500897030C71924100 @default.
• W2500897030 hasConceptScore W2500897030C98274493 @default.
• W2500897030 hasIssue "23" @default.
• W2500897030 hasLocation W25008970301 @default.
• W2500897030 hasLocation W25008970302 @default.
• W2500897030 hasOpenAccess W2500897030 @default.
• W2500897030 hasPrimaryLocation W25008970301 @default.
• W2500897030 hasRelatedWork W1896462913 @default.
• W2500897030 hasRelatedWork W2046934157 @default.
• W2500897030 hasRelatedWork W2080969318 @default.

• next